Postoperative endocrine therapy drugs for ductal carcinoma of breast, tamoxifen and toremifene have comparable efficacy, and their indications are similar to those of toremifene, which is slightly better than tamoxifen. The specific application should be analyzed with the patient’s own condition. Ductal carcinoma of breast is one of the common pathological types, which can be treated by endocrine therapy after diagnosis, and commonly used drugs such as tamoxifen and toremifene. Both are suitable for recurrent metastatic breast cancer, as well as the adjuvant treatment of metastasis after surgery to prevent recurrence; as well as estrogen receptor-positive postmenopausal women, or unknown metastatic advanced breast cancer. The efficacy of both is better, Tolimifene is slightly better than Tamoxifen, but the specific need to combine with the patient’s own condition, please apply the above drugs under the guidance of the doctor. In addition, in order to achieve a better therapeutic effect, endocrine therapy is often combined with chemotherapy, radiotherapy, targeted therapy and other therapies.